Close Menu

NEW YORK (360Dx) – Israeli in vitro diagnostics firm Todos Medical today announced a distribution deal with Orot+ for Todos' TM-B2 blood tests for breast cancer screening in Romania and Austria.

Orto+, headquartered in Tel Aviv, Israel will be responsible for the costs of marketing and distributing TM-B2. Todos will use data from the commercialization efforts to support further development and commercialization of the test in other geographies, it said. Additional terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.